In today's show, we're delighted to welcome back Charles Fisher, CEO at unlearn.ai in San Francisco. Founded in 2017, Unlearn helps biopharma companies develop drugs more ethically and efficiently by leveraging generative machine learning models to reduce the number of patients required for placebo controls in clinical trials. They enable clinical trial sponsors to run RCTs that are up to twice as fast, require fewer participants, produce better evidence about therapeutic efficacy, and in which fewer participants need to be given placebos.

Charles is a scientist with interests at the intersection of physics, machine learning and computational biology. Previously, Charles worked as a machine learning engineer at Leap Motion and was a computational biologist at Pfizer. He was a Philippe Meyer Fellow in theoretical physics at École Normale Supérieure in Paris, France and a postdoctoral scientist in biophysics at Boston University. Charles holds a Ph.D. in biophysics from Harvard University and a B.S. in biophysics from the University of Michigan.

In the episode, Charles will talk about:

The work they do in medical research,

Their success over the past 12 months,

Goals they are working towards in the next year,

Plans for growing the team,

How they attract top talent to the company and

The vision for the future at unlearn.ai